Company / Cash & Equivalents
Envista Holdings Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.2B
FY2025
5-year range
$606.9M / $1.2B
FY2021-FY2025
Trend
+13.3%
vs FY2024
Sector context
#26 of 152
Health Care
What the data says
Envista Holdings's cash & equivalents of $1.2B is higher than 83% of companies in the Health Care sector (FY2025). Cash & Equivalents has increased for 3 consecutive years, from $607M in FY2022 to $1.2B in FY2025.
Based on SEC 10-K filings.
$1.2B in FY2025 with a 5-year CAGR of +6.4%. Top quartile in the Health Care sector.
Improved from $940M to $1.2B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +25.9%
- 5-Year CAGR
- +6.4%
- 10-Year CAGR
- -
Sector benchmark
+3.1% above sector average
Key checks
Key Insights
- Envista Holdings's cash & equivalents has grown for 3 consecutive years.
- 5-year CAGR of +6.4%, indicating consistent growth.
- In FY2025, cash & equivalents increased 13.3% year-over-year.
- Ranks #26 out of 152 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.2B | +13.3% |
| FY2024 | $1.1B | +13.7% |
| FY2023 | $940.0M | +54.9% |
| FY2022 | $606.9M | -43.5% |
| FY2021 | $1.1B | +20.8% |
| FY2020 | $888.9M | +320.9% |
| FY2019 | $211.2M | - |
| FY2018 | $0 | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026